MARKER THERAPEUTICS, INC. Share-based Payment Arrangement, Accelerated Cost
MARKER THERAPEUTICS, INC. (MRKR) reported Share-based Payment Arrangement, Accelerated Cost of $300.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost · last filed 2026-08-14
- MARKER THERAPEUTICS, INC. share-based payment arrangement, accelerated cost for the quarter ending 2025-06-30 was $300.00K.
- MARKER THERAPEUTICS, INC. share-based payment arrangement, accelerated cost for the quarter ending 2025-03-31 was $300.00K.
- MARKER THERAPEUTICS, INC. share-based payment arrangement, accelerated cost for fiscal 2025 was $300.00K.
| Period end | Share-based Payment Arrangement, Accelerated Cost 3 month | Share-based Payment Arrangement, Accelerated Cost 6 month | Share-based Payment Arrangement, Accelerated Cost 12 month |
|---|---|---|---|
| 2025-12-31 | $300.00K 10-K · filed 2026-03-18 | ||
| 2025-06-30 | $300.00K 10-Q · filed 2026-08-14 | $300.00K 10-Q · filed 2026-08-14 | |
| 2025-03-31 | $300.00K 10-Q · filed 2026-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |